Skip to content
Screener

Pacira BioSciences, Inc. PCRX Net product sales — Total net product sales

Other product segments

EXPAREL
$143.27M+4.9%
ZILRETTA
$26.77M+14.7%
iovera°
$6.18M+20.6%
Bupivacaine liposome injectable suspension
$1.16M-55.5%

Similar metrics at other companies

Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$176.24M+37.9%
Wabtec logo
WABProduct — Total Net Sales
$2.67B+19.9%
Carrier Global logo
CARRProduct — Total Net Sales
$5.63B+2.9%
Penguin Solutions logo
PENGProduct — Total Net Sales
$414.17M+60.1%
Spectrum Brands Holdings logo
SPBProduct sales — Net Sales
$747.6M+7.7%
Amazon logo
AMZNNet product sales — Net Sales
$71.3B+11.5%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$997.34M-11.9%
Enterprise value$1.26B+6.9%
P/E194.1×—
P/S1.4×-0.2×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemThree Months Ended March 31, 20262025
Revenues:
Net product sales$177,376$167,594
Royalty revenue—1,329
Total revenues177,376168,923
Operating expenses:
Cost of goods sold (exclusive of amortization of acquired intangible assets)36,41334,306
Research and development28,07225,342
Selling, general and administrative93,94486,776

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s net product sales — total net product sales?
Pacira BioSciences, Inc. (PCRX) reported net product sales — total net product sales of $177.38M in Q1 2026.
How has Pacira BioSciences, Inc.'s net product sales — total net product sales changed year-over-year?
Pacira BioSciences, Inc.'s net product sales — total net product sales increased by 5.8% year-over-year, from $167.59M to $177.38M.
What is the long-term trend for Pacira BioSciences, Inc.'s net product sales — total net product sales?
Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s net product sales — total net product sales has grown at a 7.6% compound annual growth rate (CAGR), from $538.97M to $722.85M.
What does net product sales — total net product sales mean?
This metric represents the total revenue generated from the sale of pharmaceutical products after accounting for returns, allowances, and rebates. It serves as a primary indicator of the company's commercial success and market adoption of its core product portfolio. Investors use this figure to evaluate the underlying demand for the company's therapeutic offerings independent of other revenue streams.

Ask your AI about Pacira BioSciences, Inc.'s net product sales — total net product sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude